Sort   by:  
 Page size 
UnknownAlendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age.
Not available
S-EPMC7442851 | biostudies-literature
UnknownPostpartum maternal monitoring for renal safety related to tenofovir exposure during breastfeeding in the PROMISE 1077BF randomized trial.
Not available
S-EPMC12758623 | biostudies-literature
UnknownBone and Renal Health in Infants With or Without Breastmilk Exposure to Tenofovir-Based Maternal Antiretroviral Treatment in the PROMISE Randomized Trial.
Not available
S-EPMC10337310 | biostudies-literature
UnknownEffect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial.
Not available
S-EPMC8378741 | biostudies-literature
UnknownImpact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Not available
S-EPMC7864465 | biostudies-literature
UnknownMaternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.
Not available
S-EPMC9297643 | biostudies-literature
UnknownImpact of Human Immunodeficiency Virus Drug Resistance Mutations Detected in Women Prior to Antiretroviral Therapy With Efavirenz + Tenofovir Disoproxil Fumarate + Lamivudine (or Emtricitabine).
Not available
S-EPMC11267229 | biostudies-literature
Sort   by:  
 Page size